Claims

1. A therapeutic drug for cancer, comprising a CBP/catenin inhibitor and an immune checkpoint inhibitor in combination, wherein the CBP/catenin inhibitor is (6S,9aS)-N-benzyl-8-((6-(3-(4-ethylpiperazin-1-yl)azetidin-1-yl)pyridin-2-yl)methyl)-6-((2-fluoro-4-hydroxyphenyl)methyl)-4,7-dioxo-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide, and the immune checkpoint inhibitor is an anti-PD-1 antibody.

2. Use of the combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor in the manufacture of a therapeutic drug for cancer, wherein the CBP/catenin inhibitor is (6S,9aS)-N-benzyl-8-((6-(3-(4-ethylpiperazin-1-yl)azetidin-1-yl)pyridin-2-yl)methyl)-6-((2-fluoro-4-hydroxyphenyl)methyl)-4,7-dioxo-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide, and the immune checkpoint inhibitor is an anti-PD-1 antibody.